A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1 alpha pathway

作者：Sagawa Morihiko; Shimizu Takatsune; Fukushima Naoshi; Kinoshita Yasuko; Ohizumi Iwao; Uno Shinsuke; Kikuchi Yasufumi; Ikeda Yasuo; Yamada Okabe Hisafumi; Kizaki Masahiro^*

来源：CANCER SCIENCE, 2011, 102(6): 1208-1215.

DOI：10.1111/j.1349-7006.2011.01925.x

CD47 belongs to the immunoglobulin superfamily and is associated with beta-integrins. Recently it was reported that CD47 ligation rapidly induces apoptosis in B-chronic lymphocytic leukemia (CLL) cells. Chronic lymphocytic leukemia is still an incurable hematological malignancy even with the novel therapeutic agents; therefore, new and effective agents for the treatment of CLL in clinical settings are urgently needed. We generated a murine monoclonal antibody against an extracellular domain of human CD47 (designated MABL). Subsequently, we created a disulfide-stabilized dimer of a single-chain antibody fragment of MABL (S-S diabody) to get rid of the adverse effect of MABL such as hemagglutination. In this study, we analyzed the effects of this new antibody on cellular proliferation, and the molecular mechanism of CD47-mediated apoptosis in human lymphoid malignant cells. Treatment with S-S diabody alone induced apoptosis of CD47-positive primary B-CLL and leukemic cells (MOLT-4 and JOK-1). In addition, administration of S-S diabody significantly prolonged the survival of severe combined immunodeficiency (SCID) mice inoculated with JOK-1 cells. In gene expression profiling of the S-S diabody-treated MOLT-4 cells, hypoxia inducible factor (HIF)-1 alpha downstream genes (RTP801 and BNIP3) were upregulated, and the mRNA expression levels of HIF-1 alpha, RTP801 and BNIP3 were increased. Knockdown of HIF-1 alpha by siRNA repressed S-S diabody-induced apoptosis in MOLT4 cells. In conclusion, CD47 will be a molecular target for the treatment of lymphoid malignancies, and S-S diabody might have potential as a novel therapeutic agent for B-CLL. (Cancer Sci 2011; 102: 1208-1215).

• 出版日期2011-6